Back to top
more

Beam Therapeutics (BEAM)

(Delayed Data from NSDQ)

$31.03 USD

31.03
1,883,819

+2.70 (9.53%)

Updated Aug 25, 2026 04:00 PM ET

After-Market: $31.19 +0.16 (0.52%) 7:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (159 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

DaVita (DVA) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Improvement in U.S. dialysis treatments per day and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the third quarter.

Zacks Equity Research

Will CRISPR Therapeutics AG (CRSP) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Beam Therapeutics Inc. (BEAM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

The Zacks Analyst Blog Highlights Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical

by Zacks Equity Research

Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical are included in this Analyst Blog.

Zacks Equity Research

Biotech Stock Roundup: BMY's Q3 Results, PTCT Up on Deal, BEAM's Restructuring News

by Zacks Equity Research

Earnings and other updates from Bristol Myers (BMY) and PTC Therapeutic (PTCT) are in focus in the biotech sector.

Zacks Equity Research

BEAM to Reprioritize Portfolio, Slash Jobs, Shares Tank

by Zacks Equity Research

BEAM announces a restructuring and portfolio reprioritization plan to focus on genome-editing candidate, BEAM-101. The company is set to reduce its workforce by almost 20%. Shares fall.

Zacks Equity Research

BEAM Focuses on Developing Gene Drug for Growth

by Zacks Equity Research

While BEAM's pipeline candidates are in early-stage clinical studies, their development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.

Zacks Equity Research

Down -20.85% in 4 Weeks, Here's Why Beam Therapeutics Inc. (BEAM) Looks Ripe for a Turnaround

by Zacks Equity Research

Beam Therapeutics Inc. (BEAM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 21.74% and 39.60%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 2.21% and 67.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?